← All trials
NCT04854759
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2021
- Primary completion
- Mar 31, 2022
- Completion date
- May 31, 2022
- First posted
- Apr 22, 2021
- Last posted
- Aug 13, 2021
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Independent Public Clinical Hospital No. 4 in LublinLead sponsor
- Independent Public Clinical Hospital No. 4 in LublinOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.